» Review paper on intermittent vs continuous treatment in the maintenance treatment setting of metastatic colorectal cancer

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

Review paper on intermittent vs continuous treatment in the maintenance treatment setting of metastatic colorectal cancer

Prof. Tanios Bekaii-Saab, Assoc. Prof. Yu Sunakawa, Dr. Sebastian Stintzing

GI CONNECT members authored a paper ‘Reconsidering the beneﬁt of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer’ with the aim to reconsider the evidence for clinical beneﬁt of intermittent versus continuous treatment in the maintenance treatment setting of mCRC and to evaluate the effect of RAS and BRAF mutational status on maintenance strategies. Access the paper published in Cancer Treatment Reviews and download slides of the key highlights.

Prof. Tanios Bekaii-Saab

Medical Oncologist

Mayo Clinic

United States (US)

Assoc. Prof. Yu Sunakawa

Medical Oncologist

St Marianna University

Japan

Dr. Sebastian Stintzing

GI Medical Oncologist

Charité Universitaetsmedizin

Germany

Prof. Tanios Bekaii-Saab

Medical Oncologist

Mayo Clinic

United States (US)

Dr. Tanios Bekaii-Saab, M.D., is Medical Oncologist at Mayo Clinic. From 2002 Dr. Bekaii-Saab joined the faculty at The Ohio State University – Arthur G. James Cancer Hospital and Solove Research Institute, where he is a tenured Professor of Medicine and Pharmacy, and section chief for the gastrointestinal cancer program. He is the chairman of the disease specific research group for the comprehensive cancer center. Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon, followed by residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research focused on gastrointestinal malignancies, molecular targeted and immune therapies. Dr. Bekaii-Saab is actively involved in professional societies including the American Society of Clinical Oncology, American Association for Cancer Research, American Society for Clinical Pharmacology and Therapeutics, and the Alliance cooperative group.

Prof. Tanios Bekaii-Saab has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr. Sebastian Stintzing

GI Medical Oncologist

Charité Universitaetsmedizin

Germany

Sebastian Stintzing (M.D.), Professor of Medicine, is Head of the Division of Oncology and Haematology, Department of Medicine (CCM), Charité Universitaetsmedizin Berlin. His research focuses on predictive and prognostic biomarkers in the treatment of GI cancer with a special focus on colorectal cancer. From 2012 to 2014, he was a research fellow at the Sharon Carpenter Laboratory at the University of Southern California Norris Comprehensive Cancer Center, Los Angeles, U.S.A. He coordinated the translational part and assisted the clinical study conduct of several studies and earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer. In 2012, he received the prestigious Research Fellowship Award from the German Cancer Aid in Germany and started work at the University of Southern California. Dr. Stintzing is member of national and international cancer associations and speaker of the steering committee of the working group Colorectal Carcinoma of the German AIO.

Dr. Sebastian Stintzing has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

time | open 0 min | 2016

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download the slides

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Prof Valentina Guarneri

Interactive patient case

28 min

(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced ...

Sep 2023

Prof. Viktor Grünwald

Interactive patient case

11 min

Optimising treatment for advanced RCC

Jun 2023

Prof. David Hong

5 min

TRK fusion-positive cancer highlights from ASCO 2022

Jun 2022

Beth Wittmer

Prof. Hans Prenen

Podcast

20 min

Podcast: management of skin toxicity with multikinase inhibitors

Jun 2022

Prof. Chiara Cremolini

2 min

Update from ASCO 2022 - Rectal cancer & mCRC

Jun 2022

Prof. Sammy Saab

15 min

Response to immunotherapy in HCC: Real-world experience and treat...

Jun 2022

Prof. Jonathan Trent

2 min

Update from ASCO 2022 - Sarcoma

Jun 2022

Prof. Jonathan Trent

0 min

[DEMO] SARCOMA CONNECT update from ASCO 2022

May 2022

Screenshot of the video by Prof. Rebecca Dent

Dr. Rebecca Dent

Prof. Chiara Cremolini

Asst. Prof. Hans Lee

Prof. Jonathan Trent

0 min

Update From ASCO 2022 - Selected LBAs

May 2022

Brenda Martone

Assoc. Prof. Alicia Morgans

Podcast

30 min

Shared decision-making in nmCRPC: Treatment considerations to mai...

Jun 2022

Assoc. Prof. Tanya Dorff

Dr. Neal Shore

Podcast

30 min

Timing of ARSI and taxanes for mCRPC

Jun 2022

Assessing the management of hepatocellular cancer in Asia

Survey

2 min

Assessing the management of hepatocellular cancer in Asia

Jun 2022

Other programmes developed by Assoc. Prof. Yu Sunakawa

Assoc. Prof. Yu Sunakawa

Medical Oncologist

St Marianna University

Japan

Asst. Prof. Joleen Hubbard

Assoc. Prof. Yu Sunakawa

5 min

Which targeted drug (bevacizumab, ramucirumab, aflibercept, or an...

2017

Assoc. Prof. Yu Sunakawa

5 min

GI CONNECT Update from ASCO GI 2020: cancers of the liver, small ...

Jan 2020

Other programmes developed by Dr. Sebastian Stintzing

Dr. Sebastian Stintzing

GI Medical Oncologist

Charité Universitaetsmedizin

Germany

Dr. Sebastian Stintzing

5 min

GI CONNECT Update from ASCO GI 2015: upper GI cancer

2015

Dr. Sebastian Stintzing

5 min

Colorectal cancer with microsatellite instability and immunothera...

2015

Dr. Sebastian Stintzing

5 min

What is the relevance of molecular subtypes in GI tumors?

2018

Dr. Shubham Pant

Dr. Thomas Winder

Dr. Sebastian Stintzing

5 min

What are the pros and cons of adjuvant treatment in stage II colo...

2018

Dr. Samuel J Klempner

Dr. Sebastian Stintzing

5 min

Locally advanced gastric cancer

2019

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.